Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03038776
Registration number
NCT03038776
Ethics application status
Date submitted
30/01/2017
Date registered
1/02/2017
Date last updated
7/05/2019
Titles & IDs
Public title
Recombinant H7 Hemagglutinin Influenza Vaccine Trial
Query!
Scientific title
A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine
Query!
Secondary ID [1]
0
0
FLU007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FLU007
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Influenza, Avian
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Recombinant influenza hemagglutinin
Experimental: 1 - Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
Experimental: 2 - Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
Experimental: 3 - Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
Experimental: 4 - Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
Experimental: 5 - Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
Experimental: 6 - Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
Other interventions: Recombinant influenza hemagglutinin
Avian H7N9 influenza vaccine
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Seroconversion
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
1 month post immunization
Query!
Primary outcome [2]
0
0
Seroprotection
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
1 month post immunization
Query!
Primary outcome [3]
0
0
Fold rise in geometric mean titer
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
1 month post immunization
Query!
Secondary outcome [1]
0
0
Safety: Frequency and severity of adverse events
Query!
Assessment method [1]
0
0
Frequency and severity of adverse events
Query!
Timepoint [1]
0
0
12 months post immunization
Query!
Secondary outcome [2]
0
0
T cell response
Query!
Assessment method [2]
0
0
Frequency of influenza specific T cells
Query!
Timepoint [2]
0
0
1 month post-immunization
Query!
Eligibility
Key inclusion criteria
- Male or female
- Age 18 years or over
- Able to provide written informed consent
- Willing and able to comply with the protocol for the duration of the study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- History of serious vaccine allergy*
- History of vasculitis, Wegener's granulomatosis, narcolepsy, Guillain Barre, SLE or
other systemic autoimmune disease that in the opinion of the investigator would make
the vaccine contraindicated
- History of chronic liver disease or liver transaminases elevated more than 3xULN
- Women of childbearing potential, unless using a reliable and appropriate contraceptive
method, specifically oral contraceptive pill, IUD or mechanical barrier device.
- Pregnant or lactating women.
- Any serious medical, social or mental condition which, in the opinion of the
investigator, would be detrimental to the subjects or the study.
- Receipt of another investigational agent within 28 days preceding initiation of
treatment.
- Individuals who have a past history of potential vaccine reactions will be
assessed by the investigator, who will decide whether any past potential
vaccine-related side are sufficiently minimal to allow vaccine administration to
proceed.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2019
Query!
Sample size
Target
150
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
Flinders University - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5042 - Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Vaxine Pty Ltd
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Australian Respiratory and Sleep Medicine Institute
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Recombinant H7 (rH7) vaccine has been shown to be poorly immunogenic in previous human
clinical trials. This study will test approaches to improve the immunogenicity of H7 vaccine,
namely use of a three dose regimen, use of a modified H7 HA sequence from which the Tregitope
has been removed (rH7m), and inclusion of delta inulin adjuvant adjuvant in the vaccine
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03038776
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Dimitar Sajkov, MD, PhD
Query!
Address
0
0
Flinders University/ARASMI
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03038776
Download to PDF